Biography and Research Information
OverviewAI-generated summary
Kimo C. Stine's research focuses on gene therapy and the study of cardiotoxicity, particularly in the context of cancer treatment. He has investigated the long-term effects of giroctocogene fitelparvovec gene therapy for severe hemophilia A, analyzing data from the Alta study over 104 weeks and presenting updated results from the phase 1/2 trial. His work also examines doxorubicin-induced cardiotoxicity, including delayed-onset subclinical cardiotoxicity in mice and the identification of microRNA-34a-5p as a potential early circulating biomarker for chronic cardiotoxicity.
Further contributions include research into predictive risk factors for myocardial injury in children treated with anthracyclines, with pilot studies exploring these factors. Stine has also been involved in resolving variants of uncertain significance in genetic testing, such as a novel germline TP53 mutation in a patient with Li-Fraumeni Syndrome. His scholarship metrics include an h-index of 27, with 83 total publications and 2,456 citations, designating him as a highly cited researcher. He has collaborated with researchers from the National Center for Toxicological Research and the University of Arkansas for Medical Sciences.
Metrics
- h-index: 27
- Publications: 83
- Citations: 2,469
Selected Publications
-
Correction: Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study (2026)
-
Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study (2025)
-
A Novel Germline TP53 Mutation in a Patient With Li-Fraumeni Syndrome: Resolving a Variant of Uncertain Significance (2021)
Collaboration Network
Top Collaborators
Varsha G. Desai
3 shared publications
- Doxorubicin‐induced delayed‐onset subclinical cardiotoxicity in mice
- MicroRNA‐34a‐5p as a promising early circulating preclinical biomarker of doxorubicin‐induced chronic cardiotoxicity
- Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study
Vikrant Vijay
United States Food and Drug Administration
3 shared publications
In database
- Doxorubicin‐induced delayed‐onset subclinical cardiotoxicity in mice
- MicroRNA‐34a‐5p as a promising early circulating preclinical biomarker of doxorubicin‐induced chronic cardiotoxicity
- Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study
Bounleut Phanavanh
National Center for Toxicological Research
3 shared publications
In database
- Doxorubicin‐induced delayed‐onset subclinical cardiotoxicity in mice
- MicroRNA‐34a‐5p as a promising early circulating preclinical biomarker of doxorubicin‐induced chronic cardiotoxicity
- Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study
Taewon Lee
Department of Mathematical Sciences (RU)
3 shared publications
- Doxorubicin‐induced delayed‐onset subclinical cardiotoxicity in mice
- MicroRNA‐34a‐5p as a promising early circulating preclinical biomarker of doxorubicin‐induced chronic cardiotoxicity
- Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study
James C. Fuscoe
National Center for Toxicological Research
3 shared publications
In database
- Doxorubicin‐induced delayed‐onset subclinical cardiotoxicity in mice
- MicroRNA‐34a‐5p as a promising early circulating preclinical biomarker of doxorubicin‐induced chronic cardiotoxicity
- Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study
Nathan Visweshwar
University of South Florida (US)
3 shared publications
- Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study
- Updated Results of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF-07055480/SB-525) Gene Therapy in Adults with Severe Hemophilia a
- Gene therapy with giroctocogene fitelparvovec for people with severe hemophilia A: a plain language summary of the 2-year results of a 5-year study
Thomas J. Harrington
University of Miami (US)
3 shared publications
- Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study
- Updated Results of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF-07055480/SB-525) Gene Therapy in Adults with Severe Hemophilia a
- Gene therapy with giroctocogene fitelparvovec for people with severe hemophilia A: a plain language summary of the 2-year results of a 5-year study
Barbara A. Konkle
University of Washington (US)
3 shared publications
- Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study
- Updated Results of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF-07055480/SB-525) Gene Therapy in Adults with Severe Hemophilia a
- Gene therapy with giroctocogene fitelparvovec for people with severe hemophilia A: a plain language summary of the 2-year results of a 5-year study
Adam Giermasz
University of California, Davis (US)
3 shared publications
- Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study
- Updated Results of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF-07055480/SB-525) Gene Therapy in Adults with Severe Hemophilia a
- Gene therapy with giroctocogene fitelparvovec for people with severe hemophilia A: a plain language summary of the 2-year results of a 5-year study
Jeremy Rupon
Pfizer (United States) (US)
3 shared publications
- Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study
- Updated Results of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF-07055480/SB-525) Gene Therapy in Adults with Severe Hemophilia a
- Gene therapy with giroctocogene fitelparvovec for people with severe hemophilia A: a plain language summary of the 2-year results of a 5-year study
G. Russo
Pfizer (United States) (US)
3 shared publications
- Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study
- Updated Results of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF-07055480/SB-525) Gene Therapy in Adults with Severe Hemophilia a
- Gene therapy with giroctocogene fitelparvovec for people with severe hemophilia A: a plain language summary of the 2-year results of a 5-year study
Li‐Jung Tseng
Pfizer (United States) (US)
3 shared publications
- Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study
- Updated Results of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF-07055480/SB-525) Gene Therapy in Adults with Severe Hemophilia a
- Gene therapy with giroctocogene fitelparvovec for people with severe hemophilia A: a plain language summary of the 2-year results of a 5-year study
Maria de los Angeles Resa
Pfizer (United States) (US)
3 shared publications
- Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study
- Updated Results of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF-07055480/SB-525) Gene Therapy in Adults with Severe Hemophilia a
- Gene therapy with giroctocogene fitelparvovec for people with severe hemophilia A: a plain language summary of the 2-year results of a 5-year study
Florence Ganne
Pfizer (United States) (US)
3 shared publications
- Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study
- Updated Results of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF-07055480/SB-525) Gene Therapy in Adults with Severe Hemophilia a
- Gene therapy with giroctocogene fitelparvovec for people with severe hemophilia A: a plain language summary of the 2-year results of a 5-year study
Delphine Agathon
Pfizer (United States) (US)
3 shared publications
- Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study
- Updated Results of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF-07055480/SB-525) Gene Therapy in Adults with Severe Hemophilia a
- Gene therapy with giroctocogene fitelparvovec for people with severe hemophilia A: a plain language summary of the 2-year results of a 5-year study
Similar Researchers
Based on overlapping research topics
David P. Douglass
University of Arkansas for Medical Sciences
Pharmacological Effects and Toxicity Studies
Cancer Treatment and Pharmacology
Metabolism and Genetic Disorders
JT Painter
University of Arkansas for Medical Sciences
Pharmacological Effects and Toxicity Studies
Cancer Treatment and Pharmacology
Cardiovascular Function and Risk Factors
David P. Douglass
University of Arkansas for Medical Sciences
Pharmacological Effects and Toxicity Studies
Cancer Treatment and Pharmacology
Cardiovascular Function and Risk Factors
Matthew Plotkin
University of Arkansas for Medical Sciences
Pharmacological Effects and Toxicity Studies
Cancer Treatment and Pharmacology
Cardiovascular Function and Risk Factors
Anna Brickell
University of Arkansas at Fayetteville
Pharmacological Effects and Toxicity Studies
Cardiovascular Function and Risk Factors
Metabolism and Genetic Disorders
Steven Webber
University of Arkansas for Medical Sciences
Cardiovascular Function and Risk Factors
Metabolism and Genetic Disorders
Child and Adolescent Health